Royalty Pharma (RPRX) Asset Utilization Ratio (2020 - 2026)
Royalty Pharma (RPRX) posted Asset Utilization Ratio of 0.12 for Q1 2026, up 1.4% sequentially from 0.12 in Q4 2025, and down 2.05% YoY from 0.13 in Q1 2025.
Royalty Pharma (RPRX) Asset Utilization Ratio (2020 - 2026) Analysis & Trends
Royalty Pharma has reported Asset Utilization Ratio for 7 years, with the latest figure at 0.12 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 2.05% year-over-year to 0.12 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.12 (down 2.05% YoY) and the FY2025 annual result came in at 0.13, down 3.93% from the prior year.
- Asset Utilization Ratio rose to 0.12 in Q1 2026 per RPRX's latest filing, from 0.12 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.15 in Q4 2023 and troughed at 0.12 in Q4 2025.
- A 5-year average of 0.13 and a median of 0.13 in 2022 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio advanced 12.59% in 2023, then slipped 14.54% in 2024.
- Over 5 years, Asset Utilization Ratio stood at 0.13 in 2022, then rose by 12.59% to 0.15 in 2023, then slipped by 14.54% to 0.12 in 2024, then slipped by 2.22% to 0.12 in 2025, then increased by 1.4% to 0.12 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.12, 0.12, and 0.12 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.13 |
| Mar 31, 2026 | 0.12 |
| Dec 31, 2025 | 0.12 |
| Sep 30, 2025 | 0.12 |
| Jun 30, 2025 | 0.13 |
| Mar 31, 2025 | 0.13 |
| Dec 31, 2024 | 0.12 |
| Sep 30, 2024 | 0.13 |
| Jun 30, 2024 | 0.13 |
| Mar 31, 2024 | 0.14 |
| Dec 31, 2023 | 0.15 |
| Sep 30, 2023 | 0.14 |
| Jun 30, 2023 | 0.14 |
| Mar 31, 2023 | 0.14 |
| Dec 31, 2022 | 0.13 |
| Sep 30, 2022 | 0.13 |
| Jun 30, 2022 | 0.13 |
| Mar 31, 2022 | 0.13 |
| Dec 31, 2021 | 0.13 |
| Sep 30, 2021 | 0.13 |